Sarcopenia Musculoskeletal Diseases
Conditions
Interventions
The SaMu study consists of three phases aimed at exploring the relationship between the salivary microbiome and sarcopenia in older adults.
Phase 1: Cross-Sectional Analysis
A cohort of 200 participa
Sponsors
Ghent University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Caucasian 2. Aged 70 years or older
Exclusion criteria
Exclusion criteria: 1. Known presence of interfering neuromuscular or osteoskeletal conditions (possibly leading to false-positive diagnosis of sarcopenia), such as stroke without full recuperation, Parkinson’s disease, spinal compression, or functional anomaly of the hands or legs 2. >10% total body weight loss over the past 6 months 3. Active malignant neoplasia 4. Status post radiation therapy in the head-neck region 5. Exposure to immunosuppressive drugs in the last 3 months before the screening visit 6. Exposure to systemic corticosteroid treatment in the last 14 days before the screening visit 7. Infection(s) requiring treatment with systemic antibiotics/antivirals/antifungals within 30 days prior to the biosampling 8. Clinically detectable active infection (e.g. respiratory or gastro-intestinal) 9. Not deeming competent to make decisions regarding their own well-being due to advanced cognitive impairment or severe psychiatric disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sarcopenia status is evaluated at baseline, as well as after 1 and 2 years. This status is treated as a continuous desirability variable, which is determined by three key components: muscle mass (assessed using bioelectrical impedance analysis), muscle strength (measured through grip dynamometry), and physical performance (evaluated through usual walking speed). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Sarcopenia status assessed using European Working Group On Sarcopenia in Older People 2 (EWGSOP2) criteria at baseline, as well as after 1 and 2 years 2. Individual sarcopenia components: muscle mass (assessed via bioelectrical impedance analysis), muscle strength (measured through grip dynamometry), and physical performance (evaluated by usual walking speed) assessed at baseline, 1 year, and 2 years 3. Muscle mass and strength measured through calf circumference 5-times sit-to-stand test at baseline, 1 year, and 2 years 4. Mortality determined through health record reviews and hetero-anamnesis at 1 year and 2 years 5. The number of hospitalisations identified via health record checks and hetero-anamnesis at 1 year and 2 years 6. Quality of life assessed using the SarQoL questionnaire at baseline, 1 year, and 2 years 7. The number of falls recorded through anamnesis and health record checks at 1 year and 2 years 8. The number of fractures tracked via anamnesis and health record checks at 1 year and 2 years 9. The incidence of institutionalisation determined through anamnesis and hetero-anamnesis at 1 year and 2 years | — |
Countries
Belgium
Contacts
Public ContactAnton De Spiegeleer
Outcome results
None listed